期刊
FASEB JOURNAL
卷 22, 期 4, 页码 1169-1178出版社
FEDERATION AMER SOC EXP BIOL
DOI: 10.1096/fj.07-9131.com
关键词
gamma-secretase; Tg2576; A beta; amyloid-beta precursor protein; leukotrienes
资金
- NIA NIH HHS [P30 AG008051, R01 AG022203, R01 AG015408-09, AG008051, P30 AG008051-14, AG15408, AG22203, R01 AG015408, R01 AG022203-05] Funding Source: Medline
5-Lipoxygenase (5LO), by producing leukotrienes, is a proinflammatory enzyme, and there is evidence suggesting that it is up-regulated with aging and may be involved in Alzheimer's disease (AD). In this paper, we studied the effect of 5LO-targeted gene disruption on the amyloid phenotype of a transgenic mouse model of AD, the Tg2576. Amyloid-beta (A beta) deposition in the brains of Tg2576 mice lacking 5LO was reduced by 64-80% compared with Tg2576 controls. This reduction was associated with a similar significant decrease in A beta levels measured by sandwich ELISA. Absence of 5LO did not induce any significant change in amyloid-beta precursor protein (APP) levels and processing, or A beta catabolic pathways. Furthermore, in vitro studies showed that 5LO activation or 5LO metabolites increase, whereas 5LO inhibition decreases, A beta formation, secondary to correspondent changes in gamma-secretase activity. These data establish for the first time a novel functional role for 5LO in the pathogenesis of AD-like amyloidosis, thereby modulating gamma-secretase activity. Our work suggests that pharmacological inhibition of 5LO could provide a novel therapeutic tool for AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据